Recurrent Hormone Receptor-Positive Breast Cancer With Multiple Sites of Distant Metastasis: A Case Report and Review of the Literature.

IF 3 Q4 ONCOLOGY
International Journal of Breast Cancer Pub Date : 2025-09-29 eCollection Date: 2025-01-01 DOI:10.1155/ijbc/5325167
Lu Li, Hui Liu, Xiangxin Huang, Haojun Luo
{"title":"Recurrent Hormone Receptor-Positive Breast Cancer With Multiple Sites of Distant Metastasis: A Case Report and Review of the Literature.","authors":"Lu Li, Hui Liu, Xiangxin Huang, Haojun Luo","doi":"10.1155/ijbc/5325167","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is one of the most common malignancies and the leading cause of cancer-related mortality among women worldwide, with hormone receptor-positive (HR+) breast cancer being the most common subtype. Current guidelines recommend endocrine therapy as the first-line treatment for HR+, human epidermal growth factor Receptor 2-negative breast cancer. In this case report, we describe a patient with HR+ breast cancer who developed bone and liver metastases after breast cancer surgery. We document the disease progression from initial treatment to managing local recurrence and treating distant metastasis using salvage chemotherapy combined with endocrine therapy. Importantly, following denosumab treatment, the patient experienced a bone flare; this presented as increased radionuclide uptake on bone scans, but was later confirmed as pseudoprogression. Furthermore, we note changes in the patient's pathology as the disease progresses.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2025 ","pages":"5325167"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500344/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijbc/5325167","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer is one of the most common malignancies and the leading cause of cancer-related mortality among women worldwide, with hormone receptor-positive (HR+) breast cancer being the most common subtype. Current guidelines recommend endocrine therapy as the first-line treatment for HR+, human epidermal growth factor Receptor 2-negative breast cancer. In this case report, we describe a patient with HR+ breast cancer who developed bone and liver metastases after breast cancer surgery. We document the disease progression from initial treatment to managing local recurrence and treating distant metastasis using salvage chemotherapy combined with endocrine therapy. Importantly, following denosumab treatment, the patient experienced a bone flare; this presented as increased radionuclide uptake on bone scans, but was later confirmed as pseudoprogression. Furthermore, we note changes in the patient's pathology as the disease progresses.

多发远处转移的复发性激素受体阳性乳腺癌1例报告及文献复习。
乳腺癌是最常见的恶性肿瘤之一,也是全球女性癌症相关死亡的主要原因,其中激素受体阳性(HR+)乳腺癌是最常见的亚型。目前的指南推荐内分泌治疗作为HR+(人表皮生长因子受体2阴性)乳腺癌的一线治疗。在本病例报告中,我们描述了一位HR+乳腺癌患者在乳腺癌手术后发生骨和肝脏转移。我们记录了从最初的治疗到局部复发和使用补救性化疗联合内分泌治疗治疗远处转移的疾病进展。重要的是,在denosumab治疗后,患者出现骨耀斑;这表现为骨扫描时放射性核素摄取增加,但后来证实为假性进展。此外,我们注意到随着疾病进展患者病理的变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
25
审稿时长
19 weeks
期刊介绍: International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信